|
Exelixis, Inc. - Company Profile Snapshot
| Company Profile: |
Exelixis, Inc. |
| Ticker: |
EXEL |
| Exchanges: |
NAS |
| 2008 Sales: |
117,860,000 |
| Major Industry: |
Miscellaneous |
| Sub Industry: |
Service Organizations |
| Country: |
UNITED STATES |
| Employees: |
676 |
Business Description
Exelixis, Inc.. The Group's principal activity is to develop innovative therapies for cancer and other serious diseases. Its pharmaceutical programs focuses on discovery and development of small molecule drugs for cancer. The Gruoup has built a multidisciplinary, integrated research and development platform that supports the complex, iterative nature of drug discovery, translational research and clinical development. Its first-generation anticancer product candidates in our clinical pipeline are Spectrum Selective Kinase Inhibitors, that have been optimized for balanced potency, specificity, tolerability and pharmacologic parameters. It operates in the United States.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
